Eileen M Shore

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8430570/publications.pdf

Version: 2024-02-01

96 papers	7,879 citations	57758 44 h-index	51608 86 g-index
100 all docs	100 docs citations	100 times ranked	3877 citing authors

#	Article	IF	Citations
1	<scp>BMP</scp> signaling and skeletal development in fibrodysplasia ossificans progressiva (<scp>FOP</scp>). Developmental Dynamics, 2022, 251, 144-157.	1.8	12
2	Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs. Bone, 2022, 154, 116237.	2.9	3
3	Dynamics of skeletal muscle-resident stem cells during myogenesis in fibrodysplasia ossificans progressiva. Npj Regenerative Medicine, 2022, 7, 5.	5.2	10
4	Heterotopic ossification â€•replacement of one tissue with another. FASEB Journal, 2022, 36, .	0.5	0
5	Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP). Developmental Biology, 2021, 470, 136-146.	2.0	7
6	Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification. Frontiers in Genetics, 2021, 12, 633206.	2.3	2
7	<scp>Nonclassic</scp> fibrodysplasia ossificans progressiva: A child from Angola with an <scp>ACVR1^{G328E}</scp> variant. American Journal of Medical Genetics, Part A, 2021, 185, 2572-2575.	1.2	1
8	Pathogenic ACVR1^{R206H} activation by Activin Aâ€‐induced receptor clustering and autophosphorylation. EMBO Journal, 2021, 40, e106317.	7.8	24
9	Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Frontiers in Endocrinology, 2021, 12, 732728.	3.5	15
10	An ACVR1 R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2021, , .	1.2	3
11	Genetics and future therapy prospects of fibrodysplasia ossificans progressiva. Medizinische Genetik, 2020, 31, 391-396.	0.2	2
12	Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone, 2020, 130, 115116.	2.9	22
13	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. Hormone Research in Paediatrics, 2020, 93, 182-196.	1.8	42
14	Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis. Bone, 2020, 140, 115539.	2.9	26
15	The Developmental Phenotype of the Great Toe in Fibrodysplasia Ossificans Progressiva. Frontiers in Cell and Developmental Biology, 2020, 8, 612853.	3.7	9
16	Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish. ELife, 2020, 9, .	6.0	26
17	Differential Vascularity in Genetic and Nonhereditary Heterotopic Ossification. International Journal of Surgical Pathology, 2019, 27, 859-867.	0.8	8
18	Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII. Bone, 2019, 128, 115042.	2.9	16

#	Article	IF	Citations
19	Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis. Journal of Bone and Mineral Research, 2019, 34, 1894-1909.	2.8	29
20	Severe digital malformations in a rare variant of fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2019, 179, 1310-1314.	1.2	5
21	Identification of the Identical Human Mutation in ACVR1 in 2 Cats With Fibrodysplasia Ossificans Progressiva. Veterinary Pathology, 2019, 56, 614-618.	1.7	7
22	Cover Image, Volume 179A, Number 7, July 2019. , 2019, 179, .		2
23	Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva. Methods in Molecular Biology, 2019, 1891, 247-255.	0.9	8
24	ACVR1^{R206H} FOP mutation alters mechanosensing and tissue stiffness during heterotopic ossification. Molecular Biology of the Cell, 2019, 30, 17-29.	2.1	30
25	Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'. ELife, 2019, 8, .	6.0	2
26	Ablation of GsÎ± signaling in osteoclast progenitor cells adversely affects skeletal bone maintenance. Bone, 2018, 109, 86-90.	2.9	9
27	A case report of mesenteric heterotopic ossification: Histopathologic and genetic findings. Bone, 2018, 109, 56-60.	2.9	6
28	Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish. Bone, 2018, 109, 225-231.	2.9	23
29	Heterotopic Ossification: The Keys to the Kingdom. Bone, 2018, 109, 1-2.	2.9	1
30	Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva. Journal of Bone and Mineral Research, 2018, 33, 269-282.	2.8	118
31	Variable signaling activity by FOP ACVR1 mutations. Bone, 2018, 109, 232-240.	2.9	38
32	Reply to: Macrophages Driving Heterotopic Ossification: Convergence of Genetically-Driven and Trauma-Driven Mechanisms. Journal of Bone and Mineral Research, 2018, 33, 367-368.	2.8	0
33	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nature Reviews Endocrinology, 2018, 14, 476-500.	9.6	224
34	Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 218-224.	2.9	36
35	Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva â€“ How Does One Tissue Become Another?. FASEB Journal, 2018, 32, 361.2.	0.5	0
36	TGF-Î² Family Signaling in Connective Tissue and Skeletal Diseases. Cold Spring Harbor Perspectives in Biology, 2017, 9, a022269.	5.5	86

#	Article	IF	Citations
37	The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call. European Journal of Medical Genetics, 2017, 60, 399-402.	1.3	9
38	IL15RA is required for osteoblast function and bone mineralization. Bone, 2017, 103, 20-30.	2.9	37
39	GsÎ± Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and Î²-Catenin Pathways. Scientific Reports, 2017, 7, 45140.	3.3	24
40	Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva. Academic Radiology, 2017, 24, 321-327.	2.5	8
41	Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opinion on Orphan Drugs, 2017, 5, 291-294.	0.8	34
42	Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. Journal of Bone and Mineral Research, 2016, 31, 1652-1665.	2.8	110
43	The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. Journal of Bone and Mineral Research, 2016, 31, 650-656.	2.8	157
44	Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Journal of Bone and Mineral Research, 2016, 31, 1666-1675.	2.8	137
45	Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine and Growth Factor Reviews, 2016, 27, 93-104.	7.2	51
46	Granting immunity to FOP and catching heterotopic ossification in the Act. Seminars in Cell and Developmental Biology, 2016, 49, 30-36.	5.0	54
47	Multiâ€system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1) Tj ETQq1 1 0.784314 rgBT /Ov 2265-2271.	1.2	33
48	Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. The Application of Clinical Genetics, 2015, 8, 37.	3.0	67
49	Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs. Molecular Genetics and Metabolism, 2015, 116, 195-203.	1.1	31
50	The Immunological Contribution to Heterotopic Ossification Disorders. Current Osteoporosis Reports, 2015, 13, 116-124.	3.6	66
51	Alk2 Regulates Early Chondrogenic Fate in Fibrodysplasia Ossificans Progressiva Heterotopic Endochondral Ossification. Stem Cells, 2014, 32, 1289-1300.	3.2	94
52	ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Human Molecular Genetics, 2014, 23, 5364-5377.	2.9	48
53	Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 437-48.	1.2	59
54	Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. DMM Disease Models and Mechanisms, 2012, 5, 756-762.	2.4	109

#	Article	IF	Citations
55	Pregnancy in fibrodysplasia ossificans progressiva. Obstetric Medicine, 2012, 5, 35-38.	1.1	5
56	CNS demyelination in fibrodysplasia ossificans progressiva. Journal of Neurology, 2012, 259, 2644-2655.	3.6	37
57	The complex craniofacial signature of fibrodysplasia ossificans progressiva: Whose handwriting is it?. American Journal of Medical Genetics, Part A, 2012, 158A, 2979-2980.	1.2	0
58	Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, orâ€"how does one tissue become another?. Wiley Interdisciplinary Reviews: Developmental Biology, 2012, 1, 153-165.	5.9	33
59	An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. Journal of Bone and Mineral Research, 2012, 27, 1746-1756.	2.8	157
60	Role of Altered Signal Transduction in Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva. Current Osteoporosis Reports, 2011, 9, 83-88.	3.6	30
61	Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. Orphanet Journal of Rare Diseases, 2011, 6, 80.	2.7	231
62	Osteoinductive signals and heterotopic ossification. Journal of Bone and Mineral Research, 2011, 26, 1163-1165.	2.8	14
63	Substance P signaling mediates BMP-dependent heterotopic ossification. Journal of Cellular Biochemistry, 2011, 112, 2759-2772.	2.6	99
64	In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP. Cells Tissues Organs, 2011, 194, 291-295.	2.3	65
65	Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2010, 92, 686-691.	3.0	169
66	Inherited human diseases of heterotopic bone formation. Nature Reviews Rheumatology, 2010, 6, 518-527.	8.0	220
67	Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva. Journal of Biological Chemistry, 2009, 284, 7149-7156.	3.4	184
68	Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Human Mutation, 2009, 30, 379-390.	2.5	364
69	The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine and Growth Factor Reviews, 2009, 20, 399-407.	7.2	60
70	Identification of Progenitor Cells That Contribute to Heterotopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2009, 91, 652-663.	3.0	278
71	The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. Journal of Clinical Investigation, 2009, 119, 3462-72.	8.2	178
72	Dysregulated BMP Signaling and Enhanced Osteogenic Differentiation of Connective Tissue Progenitor Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 2008, 23, 305-313.	2.8	135

#	Article	IF	Citations
73	Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). Journal of Bone and Mineral Metabolism, 2008, 26, 521-530.	2.7	73
74	Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone, 2008, 43, 427-433.	2.9	117
75	Early Diagnosis of Fibrodysplasia Ossificans Progressiva. Pediatrics, 2008, 121, e1295-e1300.	2.1	151
76	Proximal Tibial Osteochondromas in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2008, 90, 366-374.	3.0	71
77	Hematopoietic Stem-Cell Contribution to Ectopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2007, 89, 347-357.	3.0	102
78	Functional Modeling of the ACVR1 (R206H) Mutation in FOP. Clinical Orthopaedics and Related Research, 2007, 462, 87-92.	1.5	86
79	A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics, 2006, 38, 525-527.	21.4	1,079
80	Developmental Anomalies of the Cervical Spine in Patients With Fibrodysplasia Ossificans Progressiva Are Distinctly Different From Those in Patients With Klippel-Feil Syndrome. Spine, 2005, 30, 1379-1385.	2.0	89
81	Fibrodysplasia Ossificans Progressiva (FOP), a Disorder of Ectopic Osteogenesis, Misregulates Cell Surface Expression and Trafficking of BMPRIA. Journal of Bone and Mineral Research, 2005, 20, 1168-1176.	2.8	103
82	The Phenotype of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 183-188.	0.8	94
83	Immunological Features of Fibrodysplasia Ossificans Progressiva and the Dysregulated BMP4 Pathway. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 189-194.	0.8	45
84	The Genetics of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 201-204.	0.8	98
85	Influenza-like Viral Illnesses and Flare-ups of Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2004, 423, 275-279.	1.5	68
86	Heterotopic Ossification. Journal of the American Academy of Orthopaedic Surgeons, The, 2004, 12, 116-125.	2.5	307
87	Bone Morphogenetic Protein-4 Regulation in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2003, 408, 331-343.	1.5	43
88	Paternally Inherited Inactivating Mutations of theGNAS1Gene in Progressive Osseous Heteroplasia. New England Journal of Medicine, 2002, 346, 99-106.	27.0	284
89	Mast cell involvement in fibrodysplasia ossificans progressiva. Human Pathology, 2001, 32, 842-848.	2.0	96
90	Osteogenic Induction in Hereditary Disorders of Heterotopic Ossification. Clinical Orthopaedics and Related Research, 2000, 374, 303-316.	1.5	20

#	Article	IF	Citations
91	GNAS1 Mutation and Cbfa1 Misexpression in a Child with Severe Congenital Platelike Osteoma Cutis. Journal of Bone and Mineral Research, 2000, 15, 2063-2073.	2.8	66
92	Deficiency of the Î±-Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	2.8	110
93	Characterization of Bone Morphogenetic Protein 4 Receptor in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 38???45.	1.5	24
94	Bone morphogenetic protein 24 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Human Pathology, 1997, 28, 339-343.	2.0	115
95	Fibrodysplasia ossificans progressiva in two half-sisters: Evidence for maternal mosaicism. , 1996, 61, 320-324.		28
96	Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva. New England Journal of Medicine, 1996, 335, 555-561.	27.0	364